Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fried

Showing results (341-350 of 383) with videos related to

Pageof 39
Sort By:
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2017
An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood SpotsJonathan B Parr, Evans K Lodge, Vera Holzmayer, et al.
Journal of Clinical Pharmacology|October 21, 2009
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis CRoy L Hawke, Sarah J Schrieber, Tedi A Soule, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
Hepatology (Baltimore, Md.)|August 3, 2020
Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for InnovationElizabeth C Verna, Marina Serper, Jaime Chu, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevirR K Sterling, A Kuo, V K Rustgi, et al.
Alimentary Pharmacology & Therapeutics|March 22, 2024
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver diseaseRohit Loomba, Ginger Clark, Jeff Teckman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo, Robert G Gish, Marion Peters, et al.
Journal of Viral Hepatitis|November 4, 2014
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studiesM P Manns, M W Fried, S Zeuzem, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Pageof 39

Showing results (341-350 of 383) with videos related to

Sort By:
Pageof 39
Hepatology Communications|October 9, 2019
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET AnalysisKavita Radhakrishnan, Adrian M Di Bisceglie, K Rajender Reddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2017
An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood SpotsJonathan B Parr, Evans K Lodge, Vera Holzmayer, et al.
Journal of Clinical Pharmacology|October 21, 2009
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis CRoy L Hawke, Sarah J Schrieber, Tedi A Soule, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
Hepatology (Baltimore, Md.)|August 3, 2020
Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for InnovationElizabeth C Verna, Marina Serper, Jaime Chu, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevirR K Sterling, A Kuo, V K Rustgi, et al.
Alimentary Pharmacology & Therapeutics|March 22, 2024
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver diseaseRohit Loomba, Ginger Clark, Jeff Teckman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo, Robert G Gish, Marion Peters, et al.
Journal of Viral Hepatitis|November 4, 2014
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studiesM P Manns, M W Fried, S Zeuzem, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseJama M Darling, Jeroen Aerssens, Gregory Fanning, et al.
Pageof 39